News about Global Pharma

Thermo Fisher Introduces CTS OpTmizer One SFM to Boost Cell Therapy Manufacturing

Thermo Fisher Scientific has introduced the Gibco CTS OpTmizer One Serum-Free Medium (CTS OpTmizer One SFM).

Global Pharma | 15/04/2024 | By Aishwarya |  729

AbbVie Announces Late-Breaking Data at AAN Supporting Long-Term Safety and Efficacy of Atogepant for Preventive Treatment of Migraine

The overall long-term safety results were consistent with the known safety profile of atogepant in chronic and episodic migraine, and no new safety signals were identified.

Global Pharma | 12/04/2024 | By Manvi |  626

Telix Pharmaceuticals Completes Acquisition of ARTMS

Telix Pharmaceuticals Ltd. has completed the acquisition of ARTMS Inc.
<br />

Global Pharma | 12/04/2024 | By Aishwarya |  663

Corvia Medical Responds to Trial Data, Emphasizes Patient Selection in Heart Failure Therapy

This therapy is currently under investigation in the global RESPONDER-HF trial of the Corvia® Atrial Shunt.

Global Pharma | 12/04/2024 | By Abha |  540

Lamassu Biotech Receives FDA Approval for Phase 1/2a Clinical Trials of Novel Cancer Therapy

This approval paves the way for the initiation of Phase 1/2a clinical trials for SA53-OS, a therapy designed to combat locally advanced metastatic p53 wild-type tumors.

Global Pharma | 12/04/2024 | By Abha |  633

Orna Therapeutics Appoints Frank Neumann as CMO

Orna Therapeutics, a biotechnology company dedicated to designing and delivering a new class of fully engineered circular RNA therapeutics (oRNA®) announced that Frank Neumann, M.D., Ph.D., will join the Company as Chief Medical Officer.

Global Pharma | 11/04/2024 | By Manvi |  523

Sen-Jam Pharmaceutical and KVK-Tech to Provide CMC for Anti-Inflammatory Injectable

Sen-Jam Pharmaceutical has entered a third strategic collaboration with KVK-Tech.

Global Pharma | 11/04/2024 | By Aishwarya |  927

Vertex Signs Agreement to Acquire Alpine Immune Sciences

Vertex Pharmaceuticals has signed a definitive agreement with Alpine Immune Sciences, a biotechnology company focused on discovering and developing innovative, protein-based immunotherapies.

Global Pharma | 11/04/2024 | By Aishwarya |  771

Healx Secures Investment Agreement with Children's Tumor Foundation

The agreement entails payments from CTF to support the advancement of Healx's AI-powered neurofibromatosis program, particularly focusing on its lead candidate, HLX-1502, slated to enter a Phase 2 clinical trial in the near future.

Global Pharma | 11/04/2024 | By Abha |  533

Nuevocor Appoints Dr. John Lee as Chief Medical Officer

In response to his appointment, Dr. Lee expressed enthusiasm about joining Nuevocor and leading the clinical development efforts for the LMNA DCM program.

Global Pharma | 11/04/2024 | By Abha |  1105